<DOC>
	<DOCNO>NCT01027728</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple oral dos CCX354-C number dose level subject stable rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy CCX 354-C Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled Phase I/II study consist two sequential stage , Stage A B . This protocol describe objective , design , procedures Stage A study . The protocol amend future sufficient data Stage A collected initiate Stage B . The protocol amendment describe objective , design , procedures Stage B study . Stage A randomized , double-blind , placebo-controlled , multi-dose , sequential dose escalation sub-study 24 subject stable RA . Three sequential dose cohort 8 subject include stage : - Cohort 1 : 100 mg CCX354-C placebo - Cohort 2 : 100 mg CCX354-C placebo - Cohort 3 : 200 mg CCX354-C placebo Safety PK data cohort review data monitoring committee ( DMC ) dose escalation next dose level . The study proceed Stage B safety tolerability profile Stage A deem acceptable DMC .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . Male female subject , age 1875 year inclusive , stable RA base American College Rheumatology ( ACR ) criterion ( see section 11.3 ) least 3 month ( subject need active RA Stage A study ) ; 2 . Subjects must stable dose methotrexate ( 7.5 25 mg/week ) take orally , subcutaneously , intramuscularly , intravenously , ≥ 8 week prior randomization ; 3 . If subject also take sulfasalazine hydroxychloroquine , subject must stable dose medication least 8 week prior randomization ; 4 . If subject corticosteroid therapy , dose must exceed 10 mg prednisone equivalent subject must stable dose least 4 week prior randomization ; 5 . Willing able give write Informed Consent comply requirement study protocol ; 6 . Negative result human immunodeficiency virus ( HIV ) screen , hepatitis B screen , hepatitis C screen ; 7 . Judged otherwise healthy Investigator , base medical history , physical examination ( include electrocardiogram [ ECG ] ) , clinical laboratory assessment ; 8 . Female subject childbearing potential , male subject partner childbearing potential , may participate adequate contraception use , least four week , administration study medication . Adequate contraception define usage least one partner barrier method contraception , together usage female partner , commence least three month prior Screening , stable regimen form hormonal contraception intrauterine device . Use abstinence alone consider adequate . Use barrier method alone consider adequate male partner vasectomize least six month prior Screening . Use doublebarrier method contraception acceptable . 1 . Diagnosed RA prior 16 year age ; 2 . Women pregnant , breastfeeding , positive serum pregnancy test Screening ; 3 . History within one year prior randomization illicit drug use ; 4 . History alcohol abuse time past ; 5 . Use infliximab , adalimumab , abatacept , certolizumab , golimumab , tocilizumab within 8 week randomization ; 6 . Use leflunomide within 6 month randomization ; 7 . Use etanercept anakinra within 4 week randomization ; 8 . Use rituximab ocrelizumab , cytotoxic agent , cyclophosphamide chlorambucil , within one year randomization ; 9 . Currently take cytochrome P450 inhibitor include protease inhibitor ritonavir , indinavir , nelfinavir , macrolide antibiotic erythromycin , telithromycin , clarithromycin , azole antifungal fluconazole , ketoconazole , itraconazole , cimetidine , nefazodone , bergamottin ( constituent grapefruit juice ) , quercetin , aprepitant , verapamil ; 10 . History presence form cancer within 10 year prior randomization , exception excise basal cell squamous cell carcinoma skin , cervical carcinoma situ breast carcinoma situ excise resect completely without evidence local recurrence metastasis ; 11 . Evidence tuberculosis base chest X ray , tuberculin skin test , QuantiFERON®TB Gold test , TSPOT®.TB test perform screening ; 12 . Presence Felty 's syndrome , psoriatic arthritis , autoimmune disease ; 13 . Major surgery ( include joint surgery ) within 12 week prior randomization ; 14 . Subject 's hemoglobin le 11 g/dL ( 6.83 mmol/L ) Screening ; 15 . Subject evidence hepatic disease ; AST , ALT , alkaline phosphatase , bilirubin &gt; 1.5 x upper limit normal ; 16 . Subject evidence renal impairment ; serum creatinine &gt; 1.5 x upper limit normal ; 17 . The subject infection require antibiotic treatment within 4 week randomization ; 18 . History presence medical psychiatric condition disease , laboratory abnormality , opinion Investigator , may place subject unacceptable risk study participation may prevent subject complete study ; 19 . Participated clinical study investigational product within 30 day prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>